Abstract
Background: Mitochondrial dynamics play a critical role in tumor progression, yet the contribution of mitochondrial fission regulator 2 (MTFR2) to endometrial cancer (EC) remains poorly defined. This study investigated the clinical relevance and functional role of MTFR2 in EC and explored its involvement in mitochondrial dynamics mediated by the dynamin-related protein 1 (Drp1)/mitochondrial fusion protein mitofusin 1 (MFN1) signaling axis. Methods: The expression levels of MTFR2 in EC tissues and normal endometrial tissues were analyzed using quantitative real-time polymerase chain reaction (qRT-PCR), Western blot, and immunohistochemistry (IHC). The effects of MTFR2 on the proliferation, apoptosis, migration, and invasion abilities of EC cells were evaluated using Cell Counting Kit-8 (CCK-8), colony formation, 5-ethynyl-2'-deoxyuridine (EdU), scratch wound healing, and Transwell assays. A nude mouse subcutaneous xenograft tumor model was constructed to verify the role of MTFR2 in vivo, and changes in the activity of the Drp1/MFN1 signaling pathway were detected. Results: MTFR2 was significantly upregulated in EC tissues associated with patient age, clinical stage, pathological type, histological grade, depth of tumor invasion, and treatment response. Overexpression of MTFR2 promoted the proliferation, clonogenicity, DNA synthesis, migration, and invasion of EC cells; in contrast, knockdown of MTFR2 inhibited these malignant phenotypes. Additionally, MTFR2 regulated the activity of the Drp1/MFN1 signaling pathway: its overexpression increased Drp1 phosphorylation and decreased MFN1 expression, whereas MTFR2 knockdown reduced Drp1 phosphorylation and increased MFN1 levels. In vivo experiments demonstrated that silencing MTFR2 significantly suppressed subcutaneous tumor growth in nude mice and reduced the expression of Ki-67 and proliferating cell nuclear antigen (PCNA) in tumor tissues. Conclusions: MTFR2 is highly expressed in EC and is correlated with a poor prognosis and aggressive tumor behavior. It promotes proliferation, apoptosis, migration, and invasion of EC cells by regulating the Drp1/MFN1 signaling pathway. This suggests that MTFR2 could potentially be a molecular target for the diagnosis and treatment of EC.

This publication has 28 references indexed in Scilit: